Literature DB >> 15767972

Eszopiclone (Lunesta), a new hypnotic.

.   

Abstract

Eszopiclone (Lunesta) is effective for treatment of insomnia for at least 6 months, with no evidence of tolerance, dependence or abuse. It has caused mild, transient memory impairment in some patients. No studies are available comparing eszopiclone with similar drugs like zolpidem (Ambien) or zaleplon (Sonata).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15767972

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.909


  6 in total

1.  Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent.

Authors:  Benjamin D Brielmaier
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-01

2.  Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.

Authors:  Geert Mayer; Sherry Wang-Weigand; Barbara Roth-Schechter; Reiner Lehmann; Corinne Staner; Markku Partinen
Journal:  Sleep       Date:  2009-03       Impact factor: 5.849

Review 3.  Sleep complaints in community-living older persons: a multifactorial geriatric syndrome.

Authors:  Carlos A Vaz Fragoso; Thomas M Gill
Journal:  J Am Geriatr Soc       Date:  2007-10-03       Impact factor: 5.562

4.  Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia.

Authors:  Gary Zammit; Sherry Wang-Weigand; Murray Rosenthal; Xuejun Peng
Journal:  J Clin Sleep Med       Date:  2009-02-15       Impact factor: 4.062

Review 5.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 6.  Eszopiclone for late-life insomnia.

Authors:  Christina S McCrae; Amanda Ross; Ashley Stripling; Natalie D Dautovich
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.